Sharemaestro company-news research for GeneDx Holdings Corp. (WGS), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Measured evidence
Company news sentiment
WGS news sentiment
GeneDx Holdings Corp.
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone48Neutral is 50
Balanced news tone
50/100 evidence confidence
100% direct company focus
2 current stories across 1 publishers
Current company news
Price moving ahead of tone
Balanced news tone is drawn from 2 fresh independent stories, including 2 company-specific items across 1 publishers.
Latest source headline GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy finance.yahoo.com · 11 Aug 2026 12:30What supports the read
2 current stories are mapped specifically to WGS.
Cross-story agreement is 81/100, indicating a comparatively coherent tape.
What tempers the read
Only 1 publisher currently contribute to the measured read.
Price is moving more forcefully than the current news tone suggests.
48/100
Weighted toneBalanced news tone
50/100
Evidence confidencebuilding confidence
100%/100
Company focus2 direct stories
81/100
Evidence agreement19/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth25
1.99 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness61
recency-weighted evidenceAgreement81
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Price is moving more forcefully than the current news tone suggests.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
News subjects
What is shaping the score
Earnings261 stories · 50%
Market update631 stories · 50%
Source mix
Where the evidence comes from
finance.yahoo.com462 stories · 100%
Recurring subjects
Subjects appearing most often
Revenue Guidance1Private Placement1Precision Medicine1Healthcare Access1Healthcare1Genetic Testing1Earnings1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#163Tone
finance.yahoo.comDirect company coverage
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
New offering integrates virtual clinicians to create a scalable channel to increase availability of GeneDx exome testing for eligible children facing specialty-care barriers GAITHERSBURG, Md., August 11, 2026--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced the launch of a new online offering designed to expand accessibility of exome testing across the U.S. at scale for pediatric patients with global developmental delay (GDD), intellectual disability (ID) or epilepsy. Families can now initiate a
Genetic TestingHealthcare AccessPrecision Medicine
- Published
- 11 Aug 2026 12:30
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#226Tone
finance.yahoo.comDirect company coverage
GeneDx Holdings (WGS) Is Up 18.4% After Reaffirming 2026 Outlook And Raising Equity From Blackstone
In early August 2026, GeneDx Holdings Corp. reported second-quarter revenue of US$114.44 million with a net loss of US$17.74 million, reaffirmed its full-year 2026 revenue outlook, and announced a private placement of 81,967 Class A shares at US$61.00 each with participation from a Blackstone affiliate. The combination of higher revenue alongside a shift from profit to loss, together with fresh equity capital from a major institutional investor, gives investors new information on GeneDx's growth ambitions, cost structure, and funding approach. Next, we'll assess how GeneDx's higher revenue but
EarningsHealthcarePrivate PlacementRevenue Guidance
- Published
- 08 Aug 2026 01:12
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.